近幾年慢性C 型肝炎 (hepatitis C virus, HCV) 的治療用藥迅速發展，注射型的干擾素時代已經過去，取而代之的是全口服劑型的直接抗病毒藥品 (direct-acting antivirals, DAAs)。其中有三種全基因型 (pangenotypic) 的DAAs，除了具備口服便利性之外，更具有不受病毒基因型與抗藥性基因限制的特性，使治療模式更為簡便。本文回溯全基因型DAAs 用於治療慢性C 型肝炎的相關文獻，瞭解其療效、安全性與交互作用特點。

Medication therapy for chronic hepatitis C virus (HCV) has evolved rapidly from an injectable interferon-based regimen to an all-oral direct-acting antivirals (DAAs) therapy. There are three pangenotypic DAAs that are no longer restricted by viral genotypes and drug resistance genes, which makes treatment more convenient. The purpose of this article is to provide a comprehensive overview of the current use of pangenotypic DAAs concerning efficacy, safety, and drug interactions.